Atnaujinkite slapukų nuostatas

Cancer Immunology and Immunotherapy: Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy [Minkštas viršelis]

3.00/5 (1 ratings by Goodreads)
Edited by (Distinguished Professor and Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USA), Edited by (Assistant Teaching Professor in Biotechnology, Bou)
  • Formatas: Paperback / softback, 548 pages, aukštis x plotis: 235x191 mm, weight: 1130 g, 120 illustrations (84 in full color); Illustrations
  • Išleidimo metai: 27-Aug-2021
  • Leidėjas: Academic Press Inc
  • ISBN-10: 0128233974
  • ISBN-13: 9780128233979
Kitos knygos pagal šią temą:
Cancer Immunology and Immunotherapy: Volume 1 of Delivery Strategies and Engineering Technologies in Cancer ImmunotherapyDidesnis paveikslėlis
  • Formatas: Paperback / softback, 548 pages, aukštis x plotis: 235x191 mm, weight: 1130 g, 120 illustrations (84 in full color); Illustrations
  • Išleidimo metai: 27-Aug-2021
  • Leidėjas: Academic Press Inc
  • ISBN-10: 0128233974
  • ISBN-13: 9780128233979
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780128233979.html
Raktažodžiai:

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited.

Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.

  • Comprehensive treaty covering all aspects of immuno-oncology (IO)
  • Novel strategies for delivery of IO therapeutics and vaccines
  • Forecasting on the future of nanotechnology and drug delivery for IO
Contributors xiii
Preface xvii
Acknowledgments xix
1 The hallmarks of cancer and immunology
1(18)
Lara Scheherazade Milane
1 Introduction
1(1)
2 Activating invasion and metastasis
2(3)
3 Resistance to cell death
5(1)
4 Evading growth suppression and sustaining proliferative signaling
6(3)
5 Genome instability and mutation and replicative immortality
9(1)
6 Angiogenesis
10(1)
7 Avoiding immune destruction and tumor-promoting inflammation
11(3)
8 Deregulated energetics
14(1)
9 Plasticity, tumor heterogeneity, quiescence, and sternness
14(1)
10 Conclusion
15(4)
References
15(4)
2 Innate and adaptive immunity in cancer
19(44)
Aatman S. Doshi
Kirtika H. Asrani
1 Introduction
20(1)
2 Innate immunity
21(7)
3 Effector mechanisms and immunotherapies modulating innate immunity pathway
28(5)
4 Adaptive immunity
33(4)
5 Recognition of antigens
37(1)
6 Costimulatory signals
37(1)
7 Adaptive immune activation
38(1)
8 Adaptive immune regulation
38(1)
9 Humoral mediated immunity
39(2)
10 Immune suppression and cancer progression
41(1)
11 Treatments modulating the adaptive immune system
42(6)
12 Conclusion
48(15)
References
49(14)
3 Inflammation and cancer
63(20)
Gerardo G. Mackenzie
1 Introduction
63(2)
2 Similarities and differences between inflammatory responses in "Physiological" conditions and "Inflammation in Cancer"
65(1)
3 Sources of inflammation during tumorigenesis
66(4)
4 Role of inflammation in tumor initiation
70(2)
5 Role of inflammation in tumor progression
72(1)
6 Role of inflammation in tumor metastasis
73(2)
7 Inflammation elicited due to cancer therapy
75(1)
8 Conclusions
76(7)
Acknowledgments
77(1)
References
77(6)
4 Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors
83(28)
Mustafa B.A. Djamgoz
Laetitia Firmenich
1 Introduction
84(5)
2 VGSC expression and function in cells of the immune system
89(4)
3 Potential of VGSC (nNavl.5) expression in immunotherapy
93(7)
4 Conclusions and future perspectives
100(11)
Acknowledgments
101(1)
References
101(10)
5 Immunoediting and cancer priming
111(26)
Taichiro Goto
1 Introduction
112(1)
2 Cancer-immunity cycle
112(5)
3 Tumors escape immunosurveillance through immunoediting
117(2)
4 Human leukocyte antigen (HLA) loss and immune escape in lung cancer evolution
119(1)
5 Heterogenous immunoediting in lung cancer
120(2)
6 Neoantigen derived from mutation
122(3)
7 Treg and tumor immunity
125(2)
8 Tumor-associated macrophages (TAMs) and tumor immunity
127(2)
9 Conclusions
129(8)
References
130(7)
6 Metabolic reprogramming and immunity in cancer
137(60)
Yu Chen
Yongsheng Li
1 Introduction
140(3)
2 Cancer immunity and immunotherapy
143(7)
3 Metabolic reprogramming and immunometabolism
150(23)
4 Conclusion and perspectives
173(24)
References
175(22)
7 Epigenetic programming of the immune responses in cancer
197(40)
Abbey A. Saadey
Amir Yousif
Hazem E. Ghoneim
1 Introduction
197(4)
2 Epigenetic mechanisms
201(7)
3 Overview of cancer-immunity cycle
208(3)
4 Epigenetic regulation of immune cells in the tumor microenvironment
211(12)
5 Epigenetic barriers to cancer immunotherapy
223(2)
6 Epigenetic reprogramming of immune cells in the tumor microenvironment
225(12)
References
226(11)
8 Cellular therapeutics in immuno-oncology
237(30)
Gulzar Ahmad
Mansoor M. Amiji
1 Introduction
237(1)
2 Chimeric antigen receptor (CAR)
238(1)
3 CAR-T cells
239(12)
4 CAR-NK cells
251(9)
5 CAR-M cells
260(2)
6 Conclusions
262(5)
References
263(4)
9 T-cell engaging bispecific antibody therapy
267(54)
Patty A. Culp
Jeremiah D. Degenhardt
Danielle E. Dettling
Chad May
1 Inherently active T-cell engagers
268(12)
2 The challenges of targeting solid tumor indications
280(4)
3 Next-generation TCEs
284(4)
4 Potential mechanisms of resistance to TCEs
288(1)
5 The limitations of preclinical in vivo efficacy models
289(9)
6 TCEs targeting solid tumors in the clinic
298(23)
References
310(11)
10 Role of microbiome in cancer immunotherapy
321(32)
Edda Russo
Federico Boem
Amedeo Amedei
1 Introduction
321(2)
2 Main immunotherapy approaches: From the past to nowadays
323(4)
3 A new emerging actor in cancer immunotherapy response: The human microbiome
327(2)
4 Crosstalk between the microbiome and immunity in cancer
329(4)
5 The "microbiome-immunity axis" influences the effectiveness of cancer immunotherapy
333(5)
6 Microbiota shaping: From molecular immunotherapy to "eco-immunotherapy"
338(3)
7 How the holobiont perspective can reshape our approach to cancer immunotherapy
341(2)
8 Conclusions
343(10)
Acknowledgment
344(1)
References
345(8)
11 STING pathway and modulation for cancer immunotherapy
353(22)
Ting Su
Nadia Tasnim Ahmed
Shurong Zhou
Xiang Liu
Guizhi Zhu
1 Introduction
353(1)
2 cGAS-STING signaling pathway in cancer
354(5)
3 Targeting the STING pathway for cancer immunotherapy
359(2)
4 Drug delivery systems for STING agonists
361(5)
5 Summary and outlook
366(9)
References
366(9)
12 Oncolytic viruses in immunotherapy
375(64)
Use Hernandez-Aguirre
Kevin A. Cassady
1 Introduction---Oncolytic viroimmunotherapy
376(1)
2 A brief history of oncolytic viruses
376(3)
3 Overview of oncolytic virotherapy
379(2)
4 Oncolytic virus safety and efficacy
381(2)
5 Viral gene expression, replication and oncolysis
383(5)
6 Immune-mediated antitumor activity
388(5)
7 Oncolytic viruses as gene expression platforms
393(1)
8 Oncolytic virus platforms and clinical trials
394(26)
9 Conclusion
420(19)
References
421(18)
13 Comparison of therapeutic strategies for immuno-oncology
439(24)
Hae Lin Jang
Shiladitya Sengupta
1 Introduction
439(1)
2 The immunological response
440(1)
3 The intrinsic immune response within a cancer cell
440(9)
4 The innate immune response
449(4)
5 The adaptive immune response
453(4)
6 B-cell immunotherapy
457(1)
7 Summary
457(6)
References
457(6)
14 Intrinsic and acquired cancer immunotherapy resistance
463(36)
Reem Saleh
Varun Sasidharan Nair
Salman M. Toor
Eyad Elkord
1 Introduction
463(1)
2 Tumor microenvironment
464(4)
3 Cancer immunotherapies
468(4)
4 Mechanisms of resistance against cancer immunotherapies
472(9)
5 Therapeutic approaches to overcome resistance
481(4)
6 Conclusions, challenges, and future perspectives
485(14)
References
486(13)
15 Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies
499(12)
Lauren M. Gauthier
1 Introduction
499(1)
2 Overview of immunotoxicity with immuno-oncology therapies
500(5)
3 Current practices and challenges in preclinical translation of IrAEs with immuno-oncology therapy
505(3)
4 Regulatory guidance for safe clinical dosing with immuno-oncology therapies
508(1)
5 Preclinical mitigation strategies for translatable prediction of IrAEs
509(1)
6 Alternative approach to defining safe clinical starting doses with immuno-oncology therapy
510(1)
7 Conclusion
511(1)
References 511(4)
Index 515
Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable. Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouvé College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.